318 related articles for article (PubMed ID: 1656759)
41. K-ras gene point mutations and p21ras immunostaining in human ovarian tumors.
Semczuk A; Postawski K; Przadka D; Rozynska K; Wrobel A; Korobowicz E
Eur J Gynaecol Oncol; 2004; 25(4):484-8. PubMed ID: 15285310
[TBL] [Abstract][Full Text] [Related]
42. Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer.
Rusch VW; Reuter VE; Kris MG; Kurie J; Miller WH; Nanus DM; Albino AP; Dmitrovsky E
J Thorac Cardiovasc Surg; 1992 Nov; 104(5):1465-9. PubMed ID: 1331621
[TBL] [Abstract][Full Text] [Related]
43. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
44. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases.
Cuatrecasas M; Villanueva A; Matias-Guiu X; Prat J
Cancer; 1997 Apr; 79(8):1581-6. PubMed ID: 9118042
[TBL] [Abstract][Full Text] [Related]
45. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium.
Mizuuchi H; Nasim S; Kudo R; Silverberg SG; Greenhouse S; Garrett CT
Cancer Res; 1992 May; 52(10):2777-81. PubMed ID: 1581890
[TBL] [Abstract][Full Text] [Related]
46. Heterogeneous distribution of K-ras-mutated epithelia in mucinous ovarian tumors with special reference to histopathology.
Mandai M; Konishi I; Kuroda H; Komatsu T; Yamamoto S; Nanbu K; Matsushita K; Fukumoto M; Yamabe H; Mori T
Hum Pathol; 1998 Jan; 29(1):34-40. PubMed ID: 9445131
[TBL] [Abstract][Full Text] [Related]
47. k-ras mutation may be an early event in mucinous ovarian tumorigenesis.
Garrett AP; Lee KR; Colitti CR; Muto MG; Berkowitz RS; Mok SC
Int J Gynecol Pathol; 2001 Jul; 20(3):244-51. PubMed ID: 11444200
[TBL] [Abstract][Full Text] [Related]
48. [Studies on the point mutation of ras oncogene in ovarian tumor].
Fujimoto I; Shimizu Y; Umezawa S; Katase K; Hirai Y; Yamauchi K; Hasumi K
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Nov; 45(11):1289-96. PubMed ID: 8258728
[TBL] [Abstract][Full Text] [Related]
49. Immunophenotype and K-RAS mutation in mucinous ovarian adenocarcinoma with mural nodule of high-grade sarcoma: case report.
Desouki MM; Fadare O; Kanbour A; Kanbour-Shakir A
Int J Gynecol Pathol; 2014 Mar; 33(2):186-90. PubMed ID: 24487474
[TBL] [Abstract][Full Text] [Related]
50. Detection and clinical correlations of ras gene mutations in human ovarian tumors.
Varras MN; Sourvinos G; Diakomanolis E; Koumantakis E; Flouris GA; Lekka-Katsouli J; Michalas S; Spandidos DA
Oncology; 1999; 56(2):89-96. PubMed ID: 9949292
[TBL] [Abstract][Full Text] [Related]
51. Endometrial carcinomas with significant mucinous differentiation associated with higher frequency of k-ras mutations: a morphologic and molecular correlation study.
Xiong J; He M; Jackson C; Ou JJ; Sung CJ; Breese V; Steinhoff MM; Quddus MR; Tejada-Berges T; Lawrence WD
Int J Gynecol Cancer; 2013 Sep; 23(7):1231-6. PubMed ID: 23851676
[TBL] [Abstract][Full Text] [Related]
52. Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of c-Ki-ras mutations.
Cuatrecasas M; Matias-Guiu X; Prat J
Am J Surg Pathol; 1996 Jun; 20(6):739-46. PubMed ID: 8651354
[TBL] [Abstract][Full Text] [Related]
53. Coamplification at lower denaturation temperature polymerase chain reaction enables selective identification of K-Ras mutations in formalin-fixed, paraffin-embedded tumor tissues without tumor-cell enrichment.
Yu S; Xie L; Hou Z; Qian X; Yu L; Wei J; Ding Y; Liu B
Hum Pathol; 2011 Sep; 42(9):1312-8. PubMed ID: 21406308
[TBL] [Abstract][Full Text] [Related]
54. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.
Hunter SM; Gorringe KL; Christie M; Rowley SM; Bowtell DD; ; Campbell IG
Clin Cancer Res; 2012 Oct; 18(19):5267-77. PubMed ID: 22891197
[TBL] [Abstract][Full Text] [Related]
55. A rapid and simple procedure for the routine detection of ras point mutations in formalin-fixed, paraffin-embedded tissues.
Slebos RJ; Boerrigter L; Evers SG; Wisman P; Mooi WJ; Rodenhuis S
Diagn Mol Pathol; 1992 Jun; 1(2):136-41. PubMed ID: 1342959
[TBL] [Abstract][Full Text] [Related]
56. [Mutational activation of H-ras and K-ras (Codon 12,61) genes in 7,12 dimethylbenz(a)anthracene induced rat ovarian tumors].
Kataoka A; Nishida T; Sugiyama T; Hirakawa N; Yakushiji M
Nihon Sanka Fujinka Gakkai Zasshi; 1993 Feb; 45(2):119-24. PubMed ID: 8429245
[TBL] [Abstract][Full Text] [Related]
57. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy.
Jimenez RE; Warshaw AL; Z'graggen K; Hartwig W; Taylor DZ; Compton CC; Fernández-del Castillo C
Ann Surg; 1999 Oct; 230(4):501-9; discussion 509-11. PubMed ID: 10522720
[TBL] [Abstract][Full Text] [Related]
58. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
Gemignani ML; Schlaerth AC; Bogomolniy F; Barakat RR; Lin O; Soslow R; Venkatraman E; Boyd J
Gynecol Oncol; 2003 Aug; 90(2):378-81. PubMed ID: 12893203
[TBL] [Abstract][Full Text] [Related]
59. [Immunohistochemical studies of ras oncogene product p21 in human ovarian tumors].
Yaginuma Y; Yamashita K
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1409-16. PubMed ID: 2685141
[TBL] [Abstract][Full Text] [Related]
60. [K-ras mutation analysis in ovarian serous borderline and malignant tumors].
Ma L; Guo LN; Liang ZY; Ren XY; Wu SF
Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):714-8. PubMed ID: 17374253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]